SWOG clinical trial number
SWOG-9349
A Randomized Phase II Trial of CHOP with G-CSF Support or ProMACE-CytaBOM with G-CSF Support for Treatment of Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Randomized Phase II Trial of CHOP with G-CSF Support or ProMACE-CytaBOM with G-CSF Support for Treatment of Non-Hodgkin's Lymphoma
Activated
09/15/1994
Closed
01/15/1997
Research committees
Lymphoma
Publication Information Expand/Collapse
2018
Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials
PMid: PMID29370458 | PMC number: PMC5963502
2014
PMid: PMID24633940 | PMC number: PMC4137041
2003
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate and high grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)
2001
Dose-intense CHOPx2 therapy of intermediate grade lymphoma -- a phase II study of the Southwest Oncology Group (SWOG)
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
5%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
10%
Open
Phase